脑转移瘤患者的癫痫发作:人群与机构层面分析
本研究基于SEER-Medicare数据库(2008-2016年,15,863例)和布莱根妇女医院/丹娜法伯癌症研究院机构数据(2000-2015年,1,453例),分析无癫痫发作的脑转移瘤患者后续癫痫发作的发生率和危险因素。结果显示SEER-Medicare队列中10.0%、机构队列中11.6%的患者发生癫痫。多因素回归提示黑色素瘤、高风险部位转移、未接受局部脑定向治疗等与癫痫风险升高相关。
要点
- 无癫痫发作的脑转移瘤患者中约10%-12%后续出现癫痫。
- 黑色素瘤(对比NSCLC)与癫痫风险升高相关。
- 高风险部位转移及未接受局部脑定向治疗与癫痫风险升高相关。
核心结论
- 无癫痫发作的脑转移瘤患者中,特定亚组(黑色素瘤、颅内病灶负荷大、高风险部位)癫痫风险升高,抗癫痫药物的作用应重新探索。
研究设计与样本
- 利用SEER-Medicare数据(2008-2016年,15,863例)和机构数据(2000-2015年,1,453例)进行回顾性队列分析。
- 采用累积发生率曲线和Fine/Gray竞争风险回归分析癫痫发生率和危险因素。
主要发现
- SEER-Medicare队列中1,588例(10.0%)发生癫痫,机构队列中169例(11.6%)发生癫痫。
- SEER-Medicare队列多因素回归:黑种人vs白种人HR 1.45(95%CI 1.22-1.73,p<0.001),城市vs非城市HR 1.41(95%CI 1.17-1.70,p<0.001),黑色素瘤vs NSCLC HR 1.44(95%CI 1.20-1.73,p<0.001),接受脑定向立体定向放疗HR 1.67(95%CI 1.44-1.94,p<0.001)。
- 机构队列多因素回归:黑色素瘤vs NSCLC HR 1.70(95%CI 1.09-2.64,p=0.02),诊断时>4个脑转移灶HR 1.60(95%CI 1.12-2.29,p=0.01),高风险部位转移HR 3.62(95%CI 1.60-8.18,p=0.002),缺乏局部脑定向治疗HR 3.08(95%CI 1.45-6.52,p=0.003)。
关键数值与推荐
- SEER-Medicare队列癫痫累积发生率为10.0%,机构队列为11.6%。
- 机构队列中高风险部位转移的癫痫风险HR为3.62(95%CI 1.60-8.18,p=0.002)。
临床怎么用
- 对黑色素瘤脑转移、颅内病灶负荷大或高风险部位转移的无癫痫患者,可考虑重新评估抗癫痫药物的预防性使用。
局限性
- 回顾性研究设计可能引入选择偏倚和混杂因素。
- SEER-Medicare数据依赖行政编码,可能存在癫痫事件漏报或误分类。
- 机构队列样本量较小,部分亚组分析效能有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To test the hypothesis that subets of patients with brain metastases (BrM) without seizures at intracranial presentation are at increased risk for developing seizures, we characterized the incidence and risk factors for seizure development among seizure-naive patients with BrMs. METHODS: We identified 15,863 and 1,453 patients with BrM utilizing Surveillance, Epidemiology, and End Results (SEER)-Medicare data (2008-2016) and Brigham and Women's Hospital/Dana Farber Cancer Institute (2000-2015) institutional data, respectively. Cumulative incidence curves and Fine/Gray competing risks regression were used to characterize seizure incidence and risk factors, respectively. RESULTS: Among SEER-Medicare and institutional patients, 1,588 (10.0%) and 169 (11.6%) developed seizures, respectively. On multivariable regression of the SEER-Medicare cohort, Black vs White race (hazard ratio [HR] 1.45 [95% confidence interval (CI), 1.22-1.73], p < 0.001), urban vs nonurban residence (HR 1.41 [95% CI, 1.17-1.70], p < 0.001), melanoma vs non-small cell lung cancer (NSCLC) as primary tumor type (HR 1.44 [95% CI, 1.20-1.73], p < 0.001), and receipt of brain-directed stereotactic radiation (HR 1.67 [95% CI, 1.44-1.94], p < 0.001) were associated with greater seizure risk. On multivariable regression of the institutional cohort, melanoma vs NSCLC (HR 1.70 [95% CI, 1.09-2.64], p = 0.02), >4 BrM at diagnosis (HR 1.60 [95% CI, 1.12-2.29], p = 0.01), presence of BrM in a high-risk location (HR 3.62 [95% CI, 1.60-8.18], p = 0.002), and lack of local brain-directed therapy (HR 3.08 [95% CI, 1.45-6.52], p = 0.003) were associated with greater risk of seizure development. CONCLUSIONS: The role of antiseizure medications among select patients with BrM should be re-explored, particularly for those with melanoma, a greater intracranial disease burden, or BrM in high-risk locations.
引用
- Lamba N, Catalano PJ, Cagney DN, et al. Seizures Among Patients With Brain Metastases: A Population- and Institutional-Level Analysis. Neurology. 2021. PMID: 33402441. doi:10.1212/WNL.0000000000011459
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。